Phase 2 Pancreatitis Trial, Recruiting (NCT07681050)

Phase 2 Pancreatitis Trial, Recruiting NCT07681050 Sponsor: Duke University Condition: Pancreatitis

Printed from Voxsanity (voxsanity.com.au) — NCT07681050 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pancreatitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who have come to the emergency department with acute pancreatitis, meaning they have at least 2 of the following: severe upper abdominal pain that came on suddenly and doesn't go away, blood enzyme levels (lipase or amylase) that are at least 3 times higher than normal, or results from an abdominal scan that show signs of pancreatitis
The trial treatment must be able to be started within 24 hours of being admitted to hospital
The person joining the trial, or their legal representative, must be able to give formal consent to take part

Who may not be able to join:

People with too much potassium in their blood (a condition called hyperkalemia)
People with too much calcium in their blood, or significantly too little calcium in their blood
People with severely reduced kidney function or kidney failure (confirm with trial site for specific test values)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Samuel Francis, MD, Duke University Hospital

Phone: 919-684-5537

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07681050

Sponsor: Duke University

Phase: Phase 2

Status: Recruiting

Condition: Pancreatitis

Trial contact: 919-684-5537

More information: https://clinicaltrials.gov/study/NCT07681050

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who have come to the emergency department with acute pancreatitis, meaning they have at least 2 of the following: severe upper abdominal pain that came on suddenly and doesn't go away, blood enzyme levels (lipase or amylase) that are at least 3 times higher than normal, or results from an abdominal scan that show signs of pancreatitis
The trial treatment must be able to be started within 24 hours of being admitted to hospital
The person joining the trial, or their legal representative, must be able to give formal consent to take part

Who may not be able to join:

People with too much potassium in their blood (a condition called hyperkalemia)
People with too much calcium in their blood, or significantly too little calcium in their blood
People with severely reduced kidney function or kidney failure (confirm with trial site for specific test values)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Duke University

Registry

ClinicalTrials.gov

Start date

9 July 2026

Est. completion

1 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Serum Phosphorus Levels; Disease Severity as measured by the Revised Atlanta Classification (RAC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov